Incyclix Bio is a biotechnology company based in Durham, North Carolina, focused on the development of small molecule inhibitors targeting cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. Founded in 2020 by a team including Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman, the company aims to provide potent and selective inhibition of challenging CDK targets. This approach enables pharmaceutical companies and medical practitioners to access innovative therapeutic options, thereby enhancing treatment opportunities for cancer patients facing difficult cases. Through its research and development efforts, Incyclix Bio seeks to contribute to the advancement of cancer treatment solutions.
Incyclix Bio is a biotechnology company based in Durham, North Carolina, focused on the development of small molecule inhibitors targeting cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant cancers. Founded in 2020 by a team including Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman, the company aims to provide potent and selective inhibition of challenging CDK targets. This approach enables pharmaceutical companies and medical practitioners to access innovative therapeutic options, thereby enhancing treatment opportunities for cancer patients facing difficult cases. Through its research and development efforts, Incyclix Bio seeks to contribute to the advancement of cancer treatment solutions.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Cellective BioTherapy is a biotechnology company based in Raleigh, North Carolina, founded in April 2015 by Dr. Thomas F. Tedder. The company specializes in developing novel cellular and monoclonal antibody-based platforms aimed at treating a range of conditions, including cancer, autoimmunity, and immunodeficiency. Its primary focus is on B cell-based cellular therapies that modulate immune responses, allowing for innovative autologous immunotherapy solutions. Cellective BioTherapy's research encompasses treatments for various illnesses, such as cancers, diabetes, asthma, and both congenital and acquired immunodeficiency, as well as vaccine development. The company's approach enables the expansion of human B cells for therapeutic use, ensuring that essential immune cells and their protective functions are preserved during treatment.
Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer. The company offers CYP17 lyase, a validated enzyme target for the treatment of CRPC and other hormonally-driven conditions, such as breast cancer, endometriosis, or congenital adrenal hyperlplasia. Its product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth–androgen biosynthesis and AR transcriptional signaling.
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.
Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured, multiple sclerosis and similar patient populations. By combining novel pharmaceutical agents with drug delivery technology, Dignify Therapeutics will redefine the treatment of these disorders and restore the dignity of voluntary excretory function for these patients.
The company was founded in 2013 and is headquartered in Raleigh, North Carolina.